Consistent with international reports,1 this group of Tourette syndrome (TS) experts has noticed a recent increase in adolescents presenting with tic-like symptoms that show a markedly atypical onset and course. These sudden-onset motor movements and vocalizations are often associated with significant impairment and disability, resulting in emergency department visits and hospitalizations for some affected youths.
The typical clinical presentation of TS has been well described.2 Tics typically onset in childhood (w4!8 years), begin with simple movements or vocalizations, progress in a rostrocaudal fashion, and increase in complexity over time. Many patients report premonitory urges that precede tics, and being able to suppress tics for brief periods. Contextual factors can also influence tic expression, both increasing and decreasing tic severity. Finally, TS affects male patients more often than female patients (4:1), and frequently presents with obsessive-compulsive symptoms and attention-deficit/hyperactivity disorder.
In contrast, the recent surge of adolescent-onset tic-like movements have a markedly atypical course and presentation.1 These atypical presentations seem to disproportionately affect adolescent female patients, without a family history of TS, who report an abrupt and explosive onset of complex motor movements and vocalizations. Common symptoms include complex limb movements, hitting/punching, forceful head movements, speaking with an accent, and/or uncharacteristically complex vocalizations including copro-and echo-phenomena. These patients generally do not report premonitory urges, and display variable ability to temporarily suppress symptoms. The pattern of comorbid conditions is also uncharacteristic and often includes anxiety and/or depressive disorders. However, similar to patients with typical TS, many report that contextual factors influence symptom expression.
Although longitudinal research findings do not support a link between streptococcal infection and tic onset or Q6 exacerbation,3 some clinicians have thought that pediatric autoimmune neuropsychiatric syndrome (PANS) may explain the atypical presentation because of the sudden symptom onset. Yet, when evaluated for PANS, patients do not have relevant clinical/laboratory findings. The ability to differentiate typical and atypical presentations of TS is complicated by a concurrent increase in the number of patients with a history of typical TS reporting a dramatic increase in tic severity, possibly related to stressors resulting from the COVID-19 pandemic such as loss of peer social supports, greater academic challenges, and/or family-related stress.
With these caveats addressed, we propose that functional movement disorder be considered in the differential diagnosis of atypical presentations of tic-like movements and vocalizations described above. Furthermore, the increased cultural visibility of TS over the past year on social media platforms may contribute to both typical and atypical symptom presentations among patients. To date “#tourette” has been viewed over 3 billion times on TikTok. “Challenge videos” (eg, “Tourette’s Alphabet Challenge”) have also gained popularity. As tics can be susceptible to suggestion (eg, mimicking) and reinforced by consequences (eg, attention), there are indeed similarities between the symptoms exhibited by patients and the social media influencers that they report following.
With regard to assessment and diagnosis, a comprehensive evaluation by a multi-disciplinary team is critical, and should include a detailed history of symptoms, age of onset, clinical course, family history, and assessment of co-occurring psychiatric/medical diagnoses. A functional assessment to identify contextual factors (eg, family, academic, and/or social stressors, daily routines, activity selection, and social media exposure) associated with symptom expression is important for the assessment and treatment of typical TS and the atypical presentation described above.
Regarding treatment, for typical presentations of TS— whether a new onset or exacerbation of existing symptoms—we recommend following AACAP’s practice parameters.4 As psychosocial stress and psychiatric comorbidity can worsen symptom severity and increase impairment, clinicians should provide psychoeducation regarding how contextual factors can influence tics and/or tic-like behaviors. Behavioral treatment including Comprehensive Behavioral Intervention for Tics (CBIT) and pharmacotherapy can be useful. CBIT includes both habit reversal training and functional interventions to reduce unwanted patterns of reinforcement that may unintentionally increase tic severity. For patients with an atypical presentation and potential influence of contextual factors, functional interventions within CBIT can determine activities associated with greater symptom expression and can assist with developing targeted interventions. For example, patients who report a worsening of tic-like symptoms after watching TS videos on social media may benefit from limited social media exposure to potentially tic-exacerbating content. For patients with atypical presentations who cannot access CBIT, motivational interviewing and cognitive behavioral therapy (CBT) can effectively reduce psychosocial stress, increase adaptive functioning, and target co-moribidty (ie, anxiety, depression) that exacerbates the expression of problematic tic-like symptoms. If a functional movement disorder diagnosis is given, other specific behavioral therapies may also be beneficial (see La Faver et al.5).
Spikes in atypical presentations of tic-like movements are not new and will likely recur. Thus, characterizing the phenomenology, investigating mechanisms underlying symptom onset, tracing the symptom trajectory to understand long-term outcomes, and developing effective treatments is of increasing importance.
1. Heyman I, Liang H, Hedderly T. COVID-19 related increase in childhood tics and tic-like attacks. Arch Dis Child. 2021;106:420-421. https://doi.org/10.1136/archdischild-2021-321748.
2. Bloch MH, Leckman JF. Clinical course of Tourette syndrome. J Psychosom Res. 2009; 67:497-501. https://doi.org/10.1016/j.jpsychores.2009.09.002.
3. Martino D, Schrag A, Anastasiou Z, et al. Association of Group A Streptococcus exposure and exacerbations of chronic tic disorders: a multinational prospective cohort study. Neurology. 2021;96:e1680-e1693. https://doi.org/10.1212/WNL. 0000000000011610.
4. Murphy TK, Lewin AB, Storch EA, Stock S. Practice parameter for the assessment and treatment of children and adolescents with tic disorders. J Am Acad Child Adolesc Psychiatry. 2013;52:1341-1359. https://doi.org/10.1016/j.jaac.2013.09.015.
5. LaFaver K, LaFrance WC, Price ME, Rosen PB, Rapaport M. Treatment of functional neurological disorder: current state, future directions, and a research agenda. CNS Spectr. 2020;1-7. https://doi.org/10.1017/S1092852920002138.
Joseph F. McGuire, PhD
Shannon M. Bennett, PhD
Christine A. Conelea, PhD
Michael B. Himle, PhD
Seonaid Anderson, PhD
Emily J. Ricketts, PhD
Matthew R. Capriotti, PhD
Adam B. Lewin, PhD
Devin C. McNulty, PhD
Laurie Gayes Thompson, PhD
Flint M. Espil, PhD
Sarah E. Nadeau, LMFT
Melanie McConnell, PhD
Douglas W. Woods, PhD
John T. Walkup, MD
John Piacentini, PhD, ABPP
Accepted August 5, 2021. Dr. McGuire is with Johns Hopkins University School of Medicine, Baltimore, Maryland. Dr. Bennett is with Weill Cornell Medicine, New York. Dr. Conelea is with the University of Minnesota School of Medicine, Minneapolis. Dr. Himle is with the University of Utah, Salt Lake City. Dr. Anderson is with Neuro-Diverse. Drs. Ricketts and Piacentini are with the University of California Los Angeles.
Dr. Capriotti and Ms. Nadeau are with San Jose State University, California. Dr. Lewin is with the University of South Florida, Hillsborough County. Drs. McNulty, Thompson, and Walkup are with Lurie Children’s Hospital, Chicago, Illinois. Dr. Espil is with Stanford University, California. Dr. McConnell is with the University of British Columbia, Vancouver, Canada. Dr. Woods is with Marquette University, Milwaukee, Wisconsin.
This work was supported by the National Institute of Mental Health (NIMH; R61MH123754 to Christine Conelea and 5K23MH113884 to Emily Ricketts).
Conceptualization: McGuire, Bennett, Ricketts, Capriotti, Lewin, McNulty, Thompson, Espil, Nadeau, McConnell, Woods, Piacentini
Writing — original draft: McGuire, Bennett, Conelea, Himle, Anderson, Piacentini
Writing — review and editing: McGuire, Bennett, Conelea, Himle, Anderson, Ricketts, Capriotti, Lewin, McNulty, Thompson, Espil, Nadeau, McConnell, Woods, Walkup, Piacentini
Disclosure: Dr. McGuire has received research support from the Tourette Association of America (TAA), the American Academy of Neurology (AAN), and the American Psychological Foundation (APF). He has served as a consultant to Bracket Global, Syneos Health, and Luminopia and has received royalties from Elsevier. Dr. Bennett has received support from TAA. Dr. Conelea has received research support from NIMH, research support from Posit Science via NIMH funded SBIR grants, and speaker’s honoraria from TAA. Dr. Himle has received research support from NIMH and TAA. He has received speaking honoraria and travel support from TAA. Dr. Ricketts has received research support from TAA and NIMH. Dr. Capriotti has received research support from TAA and AAN. He has received speaking honoraria and travel support from TAA for workshops on behavioral treatment of Tourette Syndrome. Dr. Lewin has received research support from the Centers for Disease Control and Prevention and the Ream Foundation; has served on the speaker’s bureau for TAA and the International OCD Foundation (IOCDF); has received travel support from TAA and the American Psychological Association; has received consulting fees from Bracket LLC and Mass General; has received book royalties from Springer; has received honoraria from Oxford Press, Elsevier, Springer, and the Children’s Tumor Foundation; and has reported serving on the scientific and clinical advisory board for the IOCDF, the American Psychological Association Commission on Accreditation, and the board of directors for the Florida Diabetes Camp and the American Board of Clinical Child and Adolescent Psychology. Dr. Espil has received research support from TAA and AAN. Dr. Woods has received speaker’s honoraria from TAA and royalties from Guilford Press and Oxford University Press. Dr. Walkup has received research support from the Patient- Centered Outcomes Research Institute (PCORI). He has reported being an unpaid advisor to the Anxiety Depression Association of America and the Trichotillomania Learning Center. He has reported being an unpaid Director on the Board of Directors of the Tourette Association of America. He has received royalties for books from Guilford Press and Oxford University Press and educational materials from Wolters Kluwer. He has served as a paid speaker for the American Academy of Child and Adolescent Psychiatry, the American Psychiatric Association, and the American Academy of Pediatrics. Dr. Piacentini has received grant or research support from NIMH, PCORI, Pfizer Pharmaceuticals, and the TLC Foundation for BFRBs. He has received book royalties from Guilford Press Q10 and Oxford University Press. He has received speaking honoraria and travel support from TAA and IOCDF and consultant fees from Luminopia. Drs. Anderson, McNulty, Thompson, McConnell, and Ms. Nadeau have reported no biomedical financial interests or potential conflicts of interest.
Correspondence to Joseph F. McGuire, PhD, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, 1800 Orleans Street, Baltimore, MD 21287; e-mail: [email protected]
0890-8567/$36.00/ª2021 American Academy of Child and Adolescent Psychiatry